Plasmatic coagulation and fibrinolytic system alterations in PNH: Relation to clone size

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 7, 2003, Pages 685-695

  Grünewald, Martin ^a   Siegemund, Annelie ^b   Grünewald, Anja ^a   Schmid, Anke ^a   Koksch, Mario ^b   Schöpflin, Christine ^a   Schauer, Stefanie ^a   Griesshammer, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Endogenous thrombin potential; Fibrinolytic system activation; Haemostatic system activation; Paroxysmal nocturnal haemoglobinuria; Urokinase type plasminogen activator receptor

Indexed keywords

PROCOAGULANT; THROMBIN; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE SEVERITY; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; ISCHEMIA; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CASE-CONTROL STUDIES; CELL SIZE; CLONE CELLS; FEMALE; FIBRIN; FIBRINOLYSIS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 18244426909     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200310000-00011     Document Type: Article

References (57)

1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.
2. Socié G, Mary J, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996; 348:573-577.
3. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108:470-479.
4. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000; 42:223-233.
5. Rotoli B, Bessler M, Alfinito F, del Vecchio L. Membrane proteins in paroxysmal nocturnal haemoglobinuria. Blood Rev 1993; 7:75-86.
6. Yeh ETH, Rosse WF. Paroxysmal nocturnal hemoglobinuria and the glycosyjphosphatidylinositol anchor. J Clin Invest 1994; 93:2305-2310.
7. Schrezenmeier H, Hildebrand A, Rojewski M, Häcker H, Heimpel H, Raghavachar A. Paroxysmal nocturnal haemoglobinuria: a replacement of haemopoietic tissue? Acta Haematol 2000; 103:41-48.
8. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000; 30:103-117.
9. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. J Biol Chem 1991; 266:1926-1933.
10. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273:1551-1555.
11. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992; 667:13-31.
12. Ronne E, Hoyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, et al. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res Treat 1995; 33:199-207.
13. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 86:2602-2611.
14. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-581.
15. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997; 65:285-291.
16. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70:617-624.
17. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83:589-591.
18. Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem 2000; 275:20514-20519.
19. von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323-2327.
20. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17:237-246.
21. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
22. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
23. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
24. Fujioka S, Yamada T. Varying populations of CD59-negative, partly positive, and normally positive blood cells in different cell lineages in peripheral blood of paroxysmal nocturnal hemoglobinuria patients. Am J Hematol 1994; 45:122-127.
25. Maciejewski JP, Young NS, Yu M, Anderson SA, Sloand EM. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thromb Res 1996; 83:433-447.
26. Alfinito F, Del Vecchio L, Rocco S, Boccuni P, Musto P, Rotoli B. Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. Leukemia 1996; 10:1326-1330.
27. Pakdeesuwan K, Wanachiwanawin W, Siripanyaphinyo U, Pattanapanyasat K, Wilairat P, Issaragrisil S. Immunophenotypic discrepancies between granulocytic and erythroid lineages in peripheral blood of patients with paroxysmal nocturnal haemoglobinuria. Eur J Haematol 2000; 65: 8-16.
28. Piedras J, Lopez-Karpovitch X. Flow cytometric analysis of glycosyl-phosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size. Cytometry 2000; 42:234-238.
29. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R, et al. A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin Lab Haematol 2001; 23:81-90.
30. Holada K, Simak J, Risitano AM, Maciejewski J, Young NS, Vostal JG. Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein. Blood 2002; 100:341-343.
31. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/ plasminogen activator inhibitor type 1 (PAM) complex; relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96:761-768.
32. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000; 30: 204-218.
33. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study [see comments]. Ann Intern Med 2000; 133:81-91.
34. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction [see comments]. N Engl J Med 1998; 338:79-85.
35. Kyrie PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-462.
36. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-3682.
37. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696-701.
38. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001; 85:1011-1017.
39. Gao W, Wang Z, Bai X, Li Y, Ruan C. Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 2002; 75:434-439.
40. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86:746-756.
41. Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001; 86:124-129.
42. Stephens RW, Pollanen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108:1987-1995.
43. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93:3451-3456.
44. Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemost 1992; 68:136-142.
45. Califano F, Giovanniello T, Pantone P, Campana E, Parlapiano C, Alegiani F, et al. Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 2000; 4:59-66.
46. Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2001; 7:229-233.
47. Boomsma MM, Stearns-Kurosawa DJ, Stegeman CA, Raschi E, Meroni PL, Kurosawa S, et al. Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. Clin Exp Immunol 2002; 128:187-194.
48. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30:3302-3312.
49. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-846.
50. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23-32.
51. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 1995; 74:1045-1049.
52. Dahlback B. Blood coagulation. Lancet 2000; 355:1627-1632.
53. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 1999; 84:363-368.
54. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477:349-360.
55. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364-2368.
56. Nafa K, Bessler M, Mason P, Vulliamy T, Hillmen P, Castro-Malaspina H, et al. Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. Haematologica 1996; 81:540-542.
57. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hyper-coagulable states. N Engl J Med 1999; 340:1555-1564.